Rallybio Corp
RLYB
Company Profile
Business description
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Contact
234 Church Street
Suite 1020
New HavenCT06510
USAT: +1 203 859-3820
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,924.30 | 7.00 | -0.08% |
| CAC 40 | 8,068.62 | 17.14 | -0.21% |
| DAX 40 | 24,186.49 | 108.12 | -0.45% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,649.03 | 54.13 | -0.56% |
| HKSE | 25,976.79 | 446.28 | 1.75% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 50,270.05 | 566.50 | -1.11% |
| NZX 50 Index | 13,369.75 | 37.16 | -0.28% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,635.40 | 8.50 | -0.10% |
| SSE Composite Index | 3,889.35 | 16.03 | 0.41% |